ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Advisors Approve Three New Grant Programs; RFA, PA Available.

July 5, 2002

Children’s Oncology Group Study Shows Improved Care For Childhood Brain Tumors

October 31, 2008

Breast Cancer Survivors Report More Severe Fatigue Than Healthy Women

September 28, 2007

In Brief: NIH Reviewers, Advisors To Get Increase In Honoraria; Price Leaving NCI for Maryland

March 14, 1980

NCI To Recomplete Frederick Contract To Start In 1977

October 17, 1975

Litton Loses To PRI On Largest Frederick Contract, Competing Against Hopkins For Science Program

August 27, 1982